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Ethical behavior encompasses actions that benefit both self and society. This means
that tackling antimicrobial resistance (AMR) becomes an ethical obligation, because
the prospect of declining anti-infectives affects everyone. Without preventive action,
loss of drugs that have saved lives over the past century, will condemn ourselves,
people we know, and people we don’t know, to unacceptable risk of untreatable
infection. Policies aimed at extending antimicrobial life should be considered within
an ethical framework, in order to balance the choice, range, and quality of drugs
against stewardship activities. Conserving availability and effectiveness for future use
should not compromise today’s patients. Practices such as antimicrobial prophylaxis
for healthy people ‘at risk’ should receive full debate. There are additional ethical
considerations for AMR involving veterinary care, agriculture, and relevant bio-industries.
Restrictions for farmers potentially threaten the quality and quantity of food production
with economic consequences. Antibiotics for companion animals do not necessarily
spare those used for humans. While low-income countries cannot afford much-needed
drugs, pharmaceutical companies are reluctant to develop novel agents for short-term
return only. Public demand encourages over-the-counter, internet, black market, and
counterfeit drugs, all of which compromise international control. Prescribers themselves
require educational support to balance therapeutic choice against collateral damage
to both body and environment. Predicted mortality due to AMR provides justification
for international co-operation, commitment and investment to support surveillance and
stewardship along with development of novel antimicrobial drugs. Ethical arguments for,
and against, control of antimicrobial resistance strategies are presented and discussed
in this review.
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INTRODUCTION
Antimicrobial agents play a huge role in medical practice. The facility for healthcare services to
reliably cure the infected patient has saved countless lives over the last century. Since the discovery
of penicillin by Alexander Fleming in 1928, antibiotics have revolutionized patient management,
with the 1950–1970’s known as the “golden era of antibiotics.” Medicine reached a pivotal point
in the 1960’s with the introduction of multiple agents, which could seemingly treat any infection.
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This received due comment from then US Surgeon General
who infamously declared that the threat from infection had
been relegated to the past (Infectious Diseases Society of
America [IDSA] et al., 2011). Nowadays, increasing resistance
is seen as a major problem, since there have been diminishing
numbers of novel antibiotics approved since the late 1970’s
(Infectious Diseases Society of America [IDSA] et al., 2011).
It appears that the microbial propensity to develop resistance
is occurring much faster than man’s ability to develop new
agents.
One of the first warnings of antimicrobial resistance (AMR)
came from Fleming himself during his Nobel Lecture in 1945,
even though antimicrobial therapy was a relatively new concept.
He said:
“. . . I would like to sound one note of warning. Penicillin is to all
intents and purposes non-poisonous so there is no need to worry
about giving an overdose and poisoning the patient. There may
be a danger, though, in under dosage. It is not difficult to make
microbes resistant to penicillin in the laboratory by exposing them
to concentrations not sufficient to kill them, and the same thing
has occasionally happened in the body. The time may come when
penicillin can be bought by anyone in the shops. Then there is
the danger that the ignorant man may easily under dose himself
and by exposing his microbes to non-lethal quantities of the drug
make them resistant. Here is a hypothetical illustration. Mr. X.
has a sore throat. He buys some penicillin and gives himself, not
enough to kill the streptococci but enough to educate them to
resist penicillin. He then infects his wife. Mrs. X gets pneumonia
and is treated with penicillin. As the streptococci are now resistant
to penicillin the treatment fails. Mrs. X dies. Who is primarily
responsible for Mrs. X’s death? Why Mr. X whose negligent use
of penicillin changed the nature of the microbe. There is a moral
here, and that is that if you use penicillin, use enough” (Fleming,
1945).
Fleming was correct, since this story illustrates an important
point about appropriate usage of antibiotics, but escalating
AMR deserves a much broader approach than appealing to
the moral principles of an individual. Antimicrobial agents are
unique because they are the only pharmaceutical drugs that have
transmissible loss of efficacy over time (Spellberg et al., 2016).
The world is fast approaching a time whereby people will die
from infections because there are no longer any effective drugs
(Gallagher, 2015).
This will change the face of medicine, as we know it,
since many modern medical procedures are highly dependent
upon antimicrobial protection. This might appear to be
chiefly a problem for doctors and scientists but the nature of
widespread AMR embodies a large number of ethical and moral
issues, influencing every aspect of infection management
and potentially affecting everyone. This review aims to
introduce and discuss some of the most important ethical
dilemmas associated with AMR and its control, including
national and international responsibilities, pharmaceutical
companies, prescribing, education, advertising, veterinary
and agricultural practices, infection control, and patient
behavior.
WHY ANTIMICROBIAL RESISTANCE IS
AN ETHICAL PROBLEM
The moral implications of an action or non-action constitute
the need for ethical consideration. This encompasses prevention
and control of AMR (Littmann et al., 2015). The risks from
AMR are clear – untreatable infection – and these risks are well-
established. With this knowledge comes the responsibility to act,
in order to slow resistance trends in order to provide time to find
new ways of treating infection. If nothing is done, then future
patients will be deprived of potentially lifesaving drugs. This is
unacceptable, especially after humanity has experienced a ‘golden
era of antibiotics.’
Who is accountable for action? There are both individual
and institutional responsibilities toward control of AMR.
These include healthcare prescribers, their practices and
choice of antimicrobial drug; educational organizations
that establish the qualifications required to prescribe anti-
infectives; pharmaceutical companies who develop and market
antimicrobial products; drug discovery scientists and/or the
academic institutions that support them; veterinary and
agricultural industries; ordinary people who request, buy, take
(or fail to take) antibiotics; and executives responsible for health
regions, or indeed, national bodies including current political
rulers. These will be discussed further, but the responsibility
clearly encompasses both governmental and professional
institutions as well as prescribers and their patients.
Whatever actions are chosen to redress AMR, a balance is
required between the needs of the individual and the common
good. For example, prescribers may strive to restrict drug
consumption, but benefits from decreasing AMR for future
use might condemn current patients to serious sepsis. Who
should receive antimicrobial agents and who should not? What
criteria are required to release or withhold curative or even
potential lifesaving drugs? If there is a choice between efficacy
and risk of resistance, what constitutes appropriate and prudent
prescribing? There are additional ethical dilemmas involving
antimicrobial prescribing for subsets of patients with specific
conditions, none more pertinent than prescribing powerful drugs
to terminal or elderly patients (Leibovici and Paul, 2015). Indeed,
antimicrobials used to reduce the risk of infection for some
(healthy) patient populations should be curtailed, given that
these patients are generally well (Haire and Kaldor, 2013). While
physicians have an obligation to help their patients, they are
expected to refrain from causing harm (Gillon, 1994). As with
all prescribing, a fundamental principle of beneficence may
be illustrated by the balance between therapeutic benefit and
adverse effects from the drugs prescribed. More pertinent to
antimicrobial prescribing, the term non-maleficence meaning
‘to do no harm’ or rather inflicting the least harm possible
to reach a beneficial outcome, defines the choice between
immediate benefit from anti-infectives and potential lack of
therapies for that patient in the future. This term could also
theoretically be applied to current practice of giving antibiotics
as surgical prophylaxis, perhaps a privilege in the future (Dancer,
2013b).
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Prescribing restrictions challenge traditional autonomy of
individual practitioners. Autonomy itself demonstrates an ethical
principle intimating freedom from external control or influence.
In this respect, doctors should prescribe what they believe
to be best for a patient, justifying empirical decisions with
clinical assessment, experience, and sometimes psychosocial
reasons (Dancer, 2004; Spellberg et al., 2016). Attempts at
influencing medical autonomy means that doctors may not
support restrictive policies, particularly if they feel that these
short-change a particular patient or condition, or if cost
considerations determine therapeutic choice. There remains
a fiduciary responsibility to individual patients with shared
decision-making balanced against long-term societal interests.
Patients themselves have needs, values, and preferences, and
their wishes provide a different type of challenge. Directing the
medical profession over their right to prescribe requires sensitive
diplomacy, underpinned by evidence-based science. Opposing
arguments include internet and over-the-counter sales of
antimicrobials, which circumvent the role of licensed prescribing.
Antibiotics are a shared global resource and clinicians, patients,
public health, and government are bound together by the need to
protect these drugs from misuse (Spellberg et al., 2016).
Mandated restrictions may encompass use of human agents
in veterinary and agricultural practices. Growth promotion in
animals has been banned in the European Union but not
necessarily elsewhere. Aside from food-producing animals, the
public expect antimicrobial drugs for sick pets and indeed,
wildlife. Antimicrobials are also widely used in business
and industry, with products incorporated into paints, sprays,
coatings, fabrics, and plastics. Antiseptics, now definitively
linked with antibiotic resistance, are present in a huge array of
household items (Dancer, 2013b). Thus, commerce and profit
provide universal challenges to international bodies supporting
stewardship.
There are further ethical considerations over the distribution
of antimicrobial agents. Should drugs be limited to people
based on residence in a particular healthcare facility; district;
region; or even country (Littmann et al., 2015)? Who decides
whether some patients should forfeit medicines, even though
that decision may conflict with beneficence and indeed, all the
fundamental principles of medical ethics? To a certain extent,
this is happening already, due to high pricing of specific drugs
and countries facing sanctions, wars, economic disadvantages
and/or lack of public health structures. The spread of multi-drug
resistant tuberculosis (MDRTB) through populations riddled
by HIV infection provides a good example of the latter.
Since drug resistance is not confined to one region of the
world, antimicrobial provision and management should generate
discussion and policy on a global basis (Dancer, 2013b).
Antimicrobial resistance raises further economic issues, since
increasingly resistant infections encourage clinical demand for
more spending on remaining drugs, forcing governing bodies to
consider selective funding. Expensive last-resort antibiotics may
serve only to accelerate further resistance and could challenge
supplier strategies (Littmann and Viens, 2015). Indeed, private
medicine consortia may decide to act independently of any
governmental decree. Universal access to effective antibiotics is
essential for tackling antibiotic resistance (Daulaire et al., 2015).
A related issue operates at local level, whereby some institutions
advise prescribers to choose cheaper options, even if these are
therapeutically suspect. Such practices are hardly judicial, since
they enhance the risk of persistent or recurrent infection, which
itself encourages resistance.
Controlling AMR is an on-going problem with multiple
ethical issues, with no possible single solution that does not
raise even more questions. The varied strands of medical
practice and autonomy, prescribing, access to drugs and
economic status versus increasing resistance lend themselves
to ethical interpretation at every level. The continuing process
of combating resistance requires much debate regarding the
implementation of global initiatives (Littmann and Viens, 2015).
Restricting antibiotics to benefit one stakeholder will almost
certainly affect the same or a different stakeholder further down
the line (Dancer, 2004).
PERSPECTIVES ON ANTIMICROBIAL
STEWARDSHIP
Hospitals
Antimicrobial stewardship aims to prevent unnecessary use of
drugs within healthcare (Dellit et al., 2007). Careful stewardship
also protects patients from adverse effects or reactions with
other drugs. This is approached as a predominantly scientific
problem in most hospitals, with guidelines on antibiotic
choices balanced against diagnosis, concurrent therapy, toxicity,
allergies, and length of course. A senior practitioner leads an
antimicrobial committee, supported by clinical microbiologists,
General Practitioners (GPs), infectious disease specialists and
pharmacists. For prescribers, decisions must be made over
when patients should receive antibiotics and which class or
combination would be most beneficial. Both antimicrobial
committee, with agreed policies, and prescribers, with therapeutic
choices, need to champion the collective good over individual
rights. The final decision is a trade-off between treating a sick
patient versus the admittedly nebulous effect of prolonging
therapeutic effectiveness for the future (Littmann and Viens,
2015). Prescribers can witness the impact of chosen therapy
according to patient response in the short term, but they cannot
necessarily see longer-term benefits on the local environment
emanating from careful stewardship (Dancer, 2004; Dancer et al.,
2006).
How far should a committee insist on adhesion to agreed
guidelines? Is it appropriate to ‘ban’ certain agents, while
championing others, especially if the latter are less effective?
Mandating guidelines into policy runs the risk of alienating
prescribers, however, well-intentioned. Some cases cannot
be managed using generalized guidelines. This is due to
individual patient characteristics or infection type, and/or
antibiotic susceptibility profile of the infecting pathogen(s).
There may also be institutional factors, with an on-going
outbreak or threat of one, which skews choice of therapy. Thus,
guidance should only be that; advisory rather than mandatory.
Imposition of prescribing penalties, while generally unethical,
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could conceivably challenge diagnostic skills and experience, as
well as promote defensive behavior by prescribers. If a doctor
knows he will not be penalized for denying antibiotics for a
particular patient, even if the infection risk escalates for that
patient, then the decision to withhold therapy becomes easier.
A ‘wait and see’ policy is clinically acceptable provided the patient
remains systemically well. Conversely, a potential legal challenge
could threaten balanced decision making, particularly in private
practice situations. Mandatory policies are also at risk of
censorship due to economic, rather than efficacy considerations,
which provides further ethical bias.
Stewardship would be supported better by improving the
current range and provision of infection screening processes
(Perez et al., 2014; Daulaire et al., 2015). These deliver
quicker and more accurate detection of infection and pathogen
characteristics. Diagnostic microbiology is key to providing
the information required for appropriate prescribing, because
knowing the identity of the pathogen benefits not just the
affected patient but future patients. Correct therapy reduces
the risk of spread. Unfortunately, rapid microbiological tests
are dependent upon available resources and infrastructure of
healthcare institutions. While additional funding for expensive
molecular tests requires a thoughtful business case in developed
countries, poorer countries lack sufficient diagnostic laboratories.
Arguments for implementing or improving diagnostic provision
are dependent upon published evidence, which, in company with
infection prevention strategies, is virtually non-existent. There is
an ethical trade-off between investments in diagnostic facilities
versus potential transmission of key resistant pathogens, quite
apart from the danger of diagnostic delay for an individual
patient. You cannot control what you do not know about.
Clinical expertise starts with experience, level and quality of
the prescriber’s education. Up to 50% of antibiotics used in
United States hospitals are inappropriate, which questions the
educational curriculum underpinning medical training (Centers
for Disease Control and Prevention [CDC], 2014). If a student
does not receive basic education on microbiology, infection
control and appropriate prescribing, or understand why these are
important, then future stewardship initiatives will not achieve
ownership (Owens et al., 2009). This could be ameliorated by
introducing structured feedback on prescribing, which influences
adaptive behavior (McLellan et al., 2016). Alternatively, senior
doctors could take more responsibility for antimicrobial choice.
This could be formalized by health boards or even national
bodies, since expecting seniors to oversee antimicrobial choice
and consumption for their patients cannot be disputed on ethical
grounds. Prescribing is often left to junior doctors, who may not
have the experience to deal with complex cases.
Hospital managers report considerable structural and inter-
professional challenges to implementing antibiotic optimisation
and governance (Broom et al., 2016). Good prescribing is given
lower priority vis-à-vis other managerial issues in hospitals.
Why is this? Perhaps because there are few, if any, immediate
effects from poor choice of antimicrobial agents. Patients will get
better, or not, despite inappropriate prescribing. Secondly, there
may be antipathy between clinicians and those in managerial
positions, each misunderstanding what they do, with inevitable
loss of respect in both directions. Further, management-directed
changes are constrained by the perceived absence of a “culture
of accountability” for antimicrobial use amongst doctors. It
is clearly unethical for non-clinical managers to manipulate
prescribing in order to support a stewardship strategy but they
may feel that there is no alternative without clinical engagement.
All clinical and managerial leaders should become, and remain,
committed to controlling AMR in order to understand and
address the barriers to change. Better relationships between
clinicians and managers would help to embed a stewardship
program within the healthcare framework.
Community
Prescribers in community-based practices are less well-supported
than hospital colleagues, since they often operate in isolation.
Despite a plethora of prescribing guidance, there are many
opportunities for incorrect choice of anti-infectives as well as
over or defensive prescribing. Patients not only desire the best
and most modern of treatments, they expect a ‘pill for every
ill.’ This makes it difficult to withhold antimicrobial drugs
from the worried well, especially those who are paying for
their treatment. Doctors are more likely to prescribe drugs for
private patients, because they feel obliged to do so (Duane et al.,
2016). There may well be an ethical responsibility to challenge
prescribers over their management of private vs. public patients,
while acknowledging the tension between patient autonomy and
stewardship requirements.
The most pertinent threat to stewardship in community clinics
is time constraints. A packed waiting room will not permit
the explanation, reassurance and education required for non-
infected patients, especially parents who want something for a
sick child (Verheij, 2009). An important but largely unstated
issue in ethical guidance is to consider any possible alternatives,
or what the trade-offs from different choices may be; thus,
there are such arguments for and against stewardship initiatives.
Without time to discuss options, GPs are placed at risk of
prescribing in order to move the clinic along. Indeed, rigid
stewardship occasionally compromises the management of a
patient who really does need therapy (Kieran et al., 2011).
This is compounded by poor, or delayed, access to diagnostic
laboratories, which encourages clinicians to prescribe broader-
spectrum agents, ultimately accelerating AMR (Dancer et al.,
2015). A doctor is at risk of prescribing antibiotics ‘just in
case’ if the patient is a child, or vulnerable in some way. This
obviously compromises guidance on prescribing, although it
might protect the doctor from future legal challenge in the event
of complications. Defensive prescribing further strengthens the
need to support doctors’ decisions on anti-infectives (Duane
et al., 2016).
Like all doctors, GPs expect autonomy in their prescribing
choice; authorities challenging this require robust evidence and
recognized professional standing (Dancer, 2016). It is possible
that rigid adherence to medical beneficence fails to recognize
the risk to future patients from antimicrobial prescribing.
Most doctors are affiliated to a national professional body that
oversees practice in their specialty. There are also national
institutions that regulate doctors’ services and behavior, such
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as the United Kingdom General Medical Council (GMC).
While these organizations have ethical responsibility to define
and support antimicrobial stewardship, there have not been
any mandates issued on antimicrobial prescribing. Should
restrictions be imposed, then doctors will require education,
audit, and leadership from national bodies. These should
surmount all the barriers to stewardship already mentioned but
may still fail when challenged by workload priorities. There is
increasing interest in applying behavioral science for doctor-led
prescribing (Duane et al., 2016; McLellan et al., 2016). Social
norm feedback to prescribers can be an effective method to
reduce total antibiotic consumption in ambulatory care, despite
lack of evidence on outcomes such as resistance, appropriateness
of antibiotic use or harm from underuse (Gould and Lawes, 2016;
Hallsworth et al., 2016).
Are there ethical considerations toward allowing patients
to prescribe their own drugs? This might alleviate delays in
treatment, but there will always be a risk that the patient chooses
ineffective medication, or dose, which fails to treat the original
infection, causes adverse affects and encourages resistance. For
well-informed patients with chronic conditions, choice of therapy
can be regarded as ethically acceptable, provided they do not
change or store the drugs or donate to others. Offering a
prescription following initial consultation and asking the patient
to make a decision on a wait-and-see basis is tried and tested, with
some success (Little et al., 2014). Given support and informed
advice, patients themselves deserve some degree of autonomy, or
empowerment, toward their clinical management (Gillon, 1994).
Rigid stewardship, including prescriber penalties, might be
seen as inappropriate when undermined by private practitioners,
black market, counterfeit, over-the-counter and internet drugs
(Delepierre et al., 2012). The practice of buying antibiotics from
a shop or online, without any form of prescription, promotes
AMR because it might not be the correct drug or dose for the
user (Kobaidze et al., 2009). This illustrates an unknown and
unregulated issue for global control of AMR. Public purchase of
antimicrobial drugs challenges prescribing rights and freedom of
choice for doctors when people can obtain so-called restricted
drugs with minimal effort (McKenna, 2015). Despite this, doctors
who prescribe antibiotics online are currently at risk from GMC
investigation (Torjesen, 2016). Penalties for poor prescribing
choices could well be justified, if the objective is to spare future
patients from multi-drug resistant pathogens. This would apply
to telephone consultations as well as internet-based prescribing.
A 2014 survey conducted by the World Health Organization
(WHO) reported that of 43 European countries, 19 allowed
certain antibiotics to be purchased from pharmacies (WHO,
2014). The report concluded that pharmacists could do more
to restrict and improve antibiotic use for the public. Too many
people misunderstand the principles underlying stewardship,
which means that they do not finish the prescribed course,
demand more or alternative agents, give drugs to others, or even
stockpile agents at home (Zoorob et al., 2016). Countries in which
antibiotics can be obtained without prescription should consider
regulating the distribution of antimicrobial agents. Restrictions
such as official prescription, or auditing antibiotics purchased
online, would help national stewardship policies. If unregulated
access could be accurately monitored, then it would be easier to
target outlets of non-prescribed antimicrobial drugs, including
counterfeit agents, with intention toward international control.
Prescribing Guidelines
There are varying and contradictory differences between
antimicrobial guidelines, which tend to be couched in technical
terms and aimed at professionals such as doctors, scientists,
and pharmacists (Dellit et al., 2007). This effectively makes
them “inaccessible” to the layman and means that patients may
not understand, or know about their existence, despite the
fact that they themselves are directly affected by the contents
(Micallef et al., 2017). Non-expert stakeholders might well have
a perspective that would challenge cost issues and alternatives.
Indeed, is it morally acceptable to prescribe an agent to a
patient in order to comply with local regulations, when there is
another drug that might be more effective, or quicker, or with
fewer adverse affects? Discussion over choice, while balancing
both medical and patient autonomy, requires time during a
consultation; time, which the prescriber may not have. It is
also possible that the prescriber will not necessarily know the
full range of options and has to rely upon personal beliefs and
experience, as well as any guidelines at hand.
Most guidelines focus on hospitals, rather than community,
since the risk of generating resistance is assumed to be greater
in environments that are heavily exposed to antimicrobials. GP
prescribing is not thought to constitute the same degree of risk
as a hospital patient receiving powerful parenteral agents. This
may erode support for stewardship principles in the community.
Furthermore, the long-term effects of over or inappropriate
prescribing in the community are far more difficult to monitor
than for hospital environments. Each prescription, community or
hospital, will ultimately exert an effect on the local environment,
whether measurable or not. Repeated antibiotic courses for
community-based patients has been shown to precipitate hospital
admission due to multi-drug resistant organisms (Hillier et al.,
2007; Costelloe et al., 2010).
Guidelines might exhort prescribers to prescribe more
carefully but these are not mandatory policy (Duane et al.,
2016). Doctors can still prescribe their preferred drug without
recourse, unless they can be held accountable for their choice. The
quality of guidance itself is important, since conflicting advice
provides justification for using ‘favorite’ antibiotics. Restrictive
guidelines do not necessarily guarantee the correct choice of drug.
Prescribers may also know of previous resistance demonstrated
by a particular patient or locally circulating pathogen and use
this to circumvent guidelines (Duane et al., 2016). While there
may be a strong moral argument to choose unusual or second-
line drugs, a prescriber could be placed at risk of penalty unless
relevant and timely confirmation is received from the diagnostic
laboratory. This demands a degree of courage (and experience)
among prescribers, as well as the necessary diagnostic support.
There is good evidence to show that restrictive and enabling
interventions empower doctors to both reduce and improve
antimicrobial prescribing, although the most effective behavioral
techniques do not yet seem to be widely implemented (Rawson
et al., 2017).
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Agricultural and Veterinary Use of
Antibiotics
Half of the world’s consumption of antibiotics is used for animals
and agriculture. Livestock use is predicted to increase by two-
thirds between 2010 and 2030 years (Van Boeckel et al., 2002).
Whether used for growth promotion, therapy or prophylaxis,
dosing animals with antibiotics encourages worldwide AMR (Van
den Bogaard et al., 2001; Smith et al., 2002). Use of antimicrobial
agents for anything other than direct treatment of infection
should now be regarded as unethical, unless the agents chosen
are excluded from the human formulary. If bacteria develop
resistance within a food animal, then resistant strains spread
throughout the farm, colonize other livestock and persist in
the environment. Newly procured stock is at risk of acquiring
organisms from the local environment unless the farm practices
all-in all-out management or effective hygiene for contained pens.
Farmers and their families are also at risk of acquiring resistant
organisms from the animals for which they care (Levy et al.,
1976; Van den Bogaard et al., 2001). Multi-resistant bacteria
then pass along the food production chain to consumers via
abattoirs, appropriately termed ‘farm-to-fork’ (Warren et al.,
2008). Control interventions for AMR are thus traded for food
security. This illustrates an ethical impasse, which asks whether
untreatable infection, or food shortages, constitute the greater
population risk. Traditional bioethical principles cannot answer
this question easily, given that the issues are tempered by
economic status, public health, and pure luck.
Most antimicrobial consumption in agriculture is aimed
at growth promotion or infection prevention, rather than
direct treatment of infection, and this obviously raises ethical
issues. There are economic reasons for livestock workers
to use antimicrobials because production benefits could be
minimal even within optimized systems. However, controlling
consumption may be achieved with minimal losses in animal
performance. Examples from Denmark and the Netherlands
illustrate the effects of government intervention and legislation
on decreasing antimicrobial use while at the same time increasing
animal production. Denmark began to reduce antibiotic growth
promotion in 1995, eventually banning the practice in 2000
(The, 2012). In the Netherlands, a ban was not introduced until
2006, when the EU-wide ban was implemented (Speksnijder
et al., 2015). Both countries saw initial increases in therapeutic
AMR consumption, possibly from reduced prophylaxis but also
due to ambiguities in the terminology of therapeutic and non-
therapeutic use. Danish pig production increased by 47% between
1992 and 2008, with antimicrobial use decreasing by 51%;
antimicrobial use in poultry reduced by 90% between 1995 and
2008 without apparent loss in production. In the Netherlands,
antimicrobial use reduced by 56% between 2007 and 2012
without production losses. The Dutch experience suggests that
farmers shifted focus from using antimicrobials toward better
management systems, which circumvents ethical arguments over
banning antibiotics for growth promotion. The number of
Danish producers has indeed declined, suggesting that only farms
with good practices have been able to maintain profitability
since the ban (The, 2012). Clearly, well-resourced countries have
been able to reduce total antimicrobial consumption without
affecting animal production. Similar restrictions in low-income
countries, however, may compromise suboptimum farming
systems. Despite support for a global blanket ban on growth
promotion and prophylaxis, there are arguments for equivalent
need to protect food production in poorer countries (Littmann
et al., 2015). This supplies a different view toward the same
argument regarding well-resourced countries.
Therapeutic use of antimicrobial agents in veterinary medicine
is another important issue (Catry et al., 2010). As with people,
treating animals presents similar moral issues, but with the added
responsibility of balancing animal health against potential long-
term effects of AMR for humans. One of the key ethical dilemmas
in this regard is the continued use of colistin for livestock. Colistin
has been used since the 1950’s to treat a variety of conditions
caused by Gram-negative bacilli in various livestock species,
but most commonly for digestive disorders in pigs. For much
of this period, use of colistin in humans has been restricted
toward topical use and pre-operative bowel sterilization due to
its systemic toxicity. Recently, however, colistin has become a
last-line antimicrobial in human medicine for the treatment of
infections caused by carbapenemase-producing bacteria. While
it may not be possible to curtail use of colistin in veterinary
medicine, perhaps measure should be imposed to restrict the
drug for treatment rather than prophylaxis (Catry et al., 2015;
Rhouma et al., 2016). In pig production, 99% of colistin use
is for mass oral administration (European Medicines Agency,
2016), i.e., metaphylactic use, whereby groups of animals, both
sick and healthy, are treated at the same time (Trauﬄer et al.,
2014). The fact that such a precious drug of last resort is
given to healthy livestock clearly contravenes a range of judicial
arguments. However, a move toward targeted treatment would
require a significant change in the mode of administration for
livestock owners, as well as enhanced financial penalty with the
need to identify, isolate and treat individual animals.
Antibiotics for human use should not be jeopardized by
inappropriate prescribing for companion animals or livestock
(Collignon et al., 2009; FDA, 2012). As with banning growth
promotion, commitment to change may only occur through
mandatory restrictions, surveillance and testing in veterinary
practices and agriculture, including imported livestock and foods.
Ethical reasoning becomes less persuasive when challenged
by humane support for sick pets or livestock profits. Food
producers and pet owners can, if wanted, bypass local prescribing
restrictions and purchase what they want from internet or other
sources. Since their choice may be inappropriate, there is an
argument for flexibility in national guidelines, rather than a total
ban for animals.
PHARMACEUTICAL AND REGULATORY
AUTHORITIES
Pharmaceutical companies are reluctant to pursue anti-
infective development for largely economic reasons (Brogan
and Mossialos, 2013). Developing new drugs is a long and
costly process, without even the certainty of useable results
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(DiMasi et al., 2004). Antibiotics are generally used for a few
days, unlike drugs aimed at chronic disease. Even if a new
drug gains approval, healthcare systems may reserve it as a
last resort, in case resistance develops. It is even possible that
potential target sites for engineering antimicrobial activity have
already been squandered (Cormican and Vellinga, 2012). Thus,
pharmaceutical consortia are putting forward fewer resources
toward research to develop novel agents and vaccines. The
number of approved antibiotics within the United States from
1983 to 2012 continues to decline (Infectious Diseases Society of
America [IDSA] et al., 2011).
What would happen if drug companies increased the price
of antibiotics in order to pursue development of new agents?
This would force government and healthcare systems to focus
on antibiotic consumption, although there is no guarantee
that surplus income would be directed toward anti-infective
development. Price increases would create serious ethical
problems for poorer countries that have neither the money
for expensive drugs, nor the means to allocate or distribute
effective antibiotics (Laxminarayan et al., 2016). Inflated costs
would serve only to nullify any existing distribution system
and might encourage black market trade of counterfeit or time-
expired antibiotics. People would attempt to treat themselves,
with risk of chronic illness or death. A judicial government
should surely not permit a population to treat themselves.
Inappropriate choice of drugs would impact both on individual
and society, as well as encourage resistance; the latter amplified
in environments lacking sanitation or clean water. There is
a clear ethical obligation for wealthier countries to front the
cost of drugs and vaccines, so that less well-resourced countries
need contribute only a nominal fee (Brogan and Mossialos,
2013).
While regulatory barriers to antibiotic innovation are
frequently blamed for stalling antimicrobials, truly novel
antibiotics are not often shelved due to such barriers (So and
Shah, 2014). When compared with other drugs, antimicrobial
agents have both a higher success rate of US Food and Drug
Administration (FDA) drug approval and a shorter approval
time, although it is true to say that recent drugs have
usually evolved from pre-existing antimicrobial classes. Different
regulatory tiers of approval exist; depending upon the type of
trials performed and perceived unmet (urgent) need for specific
agents. In 2010, the FDA issued draft guidance calling for
scientific justification of margins in non-inferiority trials for
treating acute bacterial skin infections (FDA US Center for Drug
Evaluation and Research, 2010). This is where an established
drug is compared against a more recent version for a specific
indication, in this case, skin infection, but without the facility to
measure any new benefits (Outterson et al., 2013). While the need
for anti-infective approval is obvious, there are ethical challenges
for strategies aimed at accelerating such approval. There is a
risk that so-called non-inferiority trials might rely upon poorly
defined or unreliable outcome criteria; they certainly should not
replace superiority trials, usually involving a new antibiotic class,
and therefore potentially more valuable.
Toxicity issues will often terminate the life of an antibiotic.
Of around 60 antibiotics approved as new entities between
1980 and 2009, 43% were withdrawn as compared with
13% among non-antibiotics (Outterson et al., 2013). The
approval pathway of telithromycin, a first-in-class ketolide
antibiotic, is a case in point. There were reports of severe
liver injury linked with this drug, which heralded urgent
safety warnings and congressional investigations into the FDA’s
acceptance of fraudulent safety data and trial methods (Ross,
2007). The FDA subsequently concluded that non-inferiority
trials, then considered appropriate for telithromycin, were no
longer acceptable. There were also concerns over bedaquiline,
another first-in-class drug for multidrug-resistant tuberculosis.
Bedaquiline received accelerated approval on the basis of a
single phase II clinical trial despite a hugely inflated mortality
rate in treated subjects than for those receiving placebo
(Carome and Wolfe, 2012). Accelerated approval is not the
same as general FDA approval, however, since it comes with
strict limitations and is aimed at providing unmet need for
treatment (FDA US Food and Drug Administration, 2004). The
bioethical principles demonstrated here, concern the balance
between unmet need and the clinical safety of new drugs
(Outterson et al., 2013). No medical practitioner wishes to
invoke maleficence, even when faced with few therapeutic
options. Anxiety over diminishing antimicrobial drugs should
not permit trials to circumvent appropriate testing or regulatory
barriers.
RESPONSIBILITIES OF GOVERNING
BODIES
The United Kingdom has launched multiple activities aimed at
tackling AMR, some of which involve institutions such as the
World Health Organization (Chan, 2011; O’Neill, 2014). The
European Union and the European Federation of Pharmaceutical
Industries and Associations have created a joint project called
‘Innovative Medicines Initiative,’ which includes a program
worth €700m entitled, “New drugs for bad bugs” (Innovative
Medicines Initiative [IMI], 2015). The 2012 campaign covers
all aspects of antimicrobial development and began as a
public/private partnership intended to fund small companies to
work alongside larger companies in order to focus on antibiotic
research.
The United Kingdom Five Year Antimicrobial Resistance
Strategy (2013–2018) was developed with devolved
administrations including bodies that will be responsible
for delivering the work (O’Neill, 2014). The strategy highlights
the role of public awareness campaigns and the need to improve
sanitation and hygiene; it also mentions environmental pollution,
global surveillance, rapid diagnostics, new vaccines, market entry
rewards and innovation funding. There is discussion on
investment options and the strategies required for building
political consensus around these. The United Kingdom and
Chinese governments have each agreed to contribute 50 million
GBP (72 million USD) to a Global Innovation Fund, but this
requires international support, continued search for further
resources and methods for coordinating funding streams
(Department of Health [DOH] and UK Government, 2015).
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Governmental incentives for public/private partnerships to
promote antibiotic research could engender financial support for
small drug companies to develop new vaccines and antibiotics
(Sukkar, 2013). Smaller businesses developing novel agents may
only need a relatively small amount of financial support from
their respective governments in order to continue research
whilst maintaining viable business. If companies engaging in
antibiotic research were exempt from certain tax laws, this might
provide enough financial incentive for small to medium-sized
firms. Larger companies, pharmaceutical or otherwise, could
potentially offer investment and/or financial support to smaller
drug companies to aid innovative research (Theuretzbacher,
2012).
Increasing mortality rates due to infection caused by resistant
pathogens might confer serious economic consequences to
society from healthcare costs and diminishing tax contributions.
This hypothetical future scenario can be modeled against the
funds required to help develop novel drugs in order to offer
justification for investors and ruling bodies. What would public
reaction be to an ‘antimicrobial tax,’ for example, and would
this be ethically acceptable? Since this tax is aimed at public
protection, most people would probably support endorsement,
provided the gains receive judicial protection. Imposition of
such a tax could hardly be regarded as unethical. This assumes,
however, that the tax is directed toward antimicrobial drug
discovery and not side-tracked elsewhere.
Pharmaceutical companies themselves have a duty to provide
for their employees and that means attention to profit margins
in order to stay viable. One innovative project is the Health
Impact Fund (HIF), designed to incentivize neglected drug
development (Brogan and Mossialos, 2013). The HIF seeks to
establish a global repository that will register new medicines
and reward companies according to the burden of disease that
each drug alleviates (measured in QALY’s). In exchange for
reward payments during the first 10 years, companies may then
manufacture and distribute the drug at cost over this period. After
this, companies would allow generic manufacturing of the drug
(Hollis and Pogge, 2008).
Financial incentives could be structured to protect human
antibiotics for non-therapeutic purposes, such as growth
promotion in animal husbandry and aquaculture. A tax or
complete ban should target non-human use of antibiotics that
pose a risk of cross-species resistance. The magnitude of this
tax would make it economically unattractive to use antibiotics
for growth promotion (So and Shah, 2014). There has also been
a move toward imposing an ‘antibiotic tax’ on countries with
a global wealth above a certain level (Vågsholm and Höjgård,
2010). This would prompt richer countries to control antibiotic
consumption, as well as provide support, aid and public services
for poorer countries where AMR is more likely to develop and
spread. This is an enormous undertaking and vulnerable to
fraudulent or corrupt governments that may not correctly, or
fairly, distribute financial or other aid from wealthier countries.
Perhaps a better strategy would be a drug discovery platform
committed to sharing risks; resources; and rewards (Aiello et al.,
2006; So and Shah, 2014). Those joining this online community
would commit to a clickwrap license not to take from the research
commons, nor to privatize the product of their work (So and
Shah, 2014). Alternatively, the Access to Medicines Index is a
non-profit organization that aims to improve access to medicine
in low- and middle-income countries. It bench marks the top 10
R&D companies and highlights current methods undertaken by
leading pharmaceutical companies to address access to drugs in
poor countries.
EDUCATION, PUBLIC AWARENESS, AND
MEDIA CAMPIAGNS
Septic patients usually receive empirical broad-spectrum agents
before microbiological confirmation. Despite advances in
molecular testing, microbiology laboratories rely upon overnight
culture to characterize pathogens and this can delay targeted
clinical assessment. Doctors should review their patients’ results
and adjust therapy if necessary, including dose and length of
course. If they lack the requisite training to make these decisions,
then there is a risk that unsuitable antibiotics are given ‘just in
case.’ Current academic training may not adequately embrace
non-maleficence regarding antimicrobial therapy, and indeed,
basic microbiology teaching itself leaves much to be desired.
Many doctors lack sufficient knowledge needed for sensible
antimicrobial management (Davenport et al., 2005).
Given the importance of AMR, education on hygiene,
infection control, microbiology and prescribing need more focus
within universities, hospitals and colleges, ideally supported by
hygiene teaching in schools (Lecky et al., 2011). Such a decision
rests with governing boards responsible for a particular institute
unless national organizations impose specific recommendations.
This introduces an important ethical consideration for bodies
such as the GMC, Departments of Health and Education, Royal
Colleges, veterinary sciences and, arguably, medical and nursing
defense unions (Torjesen, 2016).
Of course, it is not just prescribers would benefit from
such education. Since AMR affects everyone, there is a strong
ethical argument for integrated teaching for all (McNulty et al.,
2012). Ordinary people could contribute a significant amount
toward combating the spread of infection, and indeed, there is
a degree of moral responsibility for them to do so (Curtis et al.,
2011). Appropriate hygienic practices for food preparation or
visiting the bathroom should be common place, underpinned
by education and safeguards for those not able to look after
themselves. People should clean their hands after contact with
surfaces likely to host pathogens, whether they are multiply
resistant or not. Publicizing awareness of AMR and infection
prevention will help GPs and pharmacists explain antibiotic use
to frustrated and uninformed customers, who fail to realize the
consequences from taking antimicrobial drugs. The public do
not always know that antibiotics fail to relieve viral infections;
or that they should not share medication with another; or hoard
or dispose of antibiotics themselves (Jamhour et al., 2017). An
appropriately targeted awareness campaign is justifiable because
it might influence socially conscious citizens (O’Neill, 2014).
Individuals may not be quite so altruistic when faced with life-
threatening infection, however. Richard Lehman tells us that if
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he acquires a resistant pathogen in hospital, he expects any, or
all, of the remaining antimicrobial agents available; regardless
of any stewardship policies (Lehman, 2016). Others demand
antimicrobial drugs for infected pets, whether or not they are
reserved for humans. This behavior demonstrates an economic
phenomenon known as the “tragedy of the commons” in which
individuals engage in behavior that benefits them at the expense
of communal interests (Hardin, 1968). A particular challenge
in reducing antibiotic use is this disconnect between individual
behavior and population level resistance. Avoiding overuse of a
global common good requires making a diffuse and unrecognized
social cost visible and felt (Gould and Lawes, 2016).
INFECTION PREVENTION AND
CONTROL
It is worth considering the courses of action available to society
without antibiotics (Dancer, 2013b). These center upon infection
prevention and control, which create their own additional ethical
considerations (Littmann et al., 2015). Microbial pathogens
are spread in a number of ways, usually through physical or
respiratory transmission and ingestion. Germs can be acquired
merely by touching contaminated surfaces, especially when
organisms display environmental longevity. Survival aids transfer
of organisms to the next item handled, until natural depletion,
demise, or removal through appropriate hygienic practices. High-
risk sites are handles, taps, electronic devices, buttons and
switches, etc. (Rheinbaben et al., 2000).
Some pathogens become airborne and as such can be directly
inhaled or acquired after settling on surfaces. If a man with a cold
coughs or sneezes into his hand, then grabs a handrail, he has
both released a pathogen into the air, and inoculated the handrail,
where it may be acquired by people in close proximity. Airborne
dispersal encourages rapid spread of microbes, especially in
crowded areas. These facts begin to assign ethical responsibility to
the individual, to behave in a hygienic fashion for self-protection,
if not to spare other people (Curtis et al., 2011). Sick folk
should minimize the risk of transmission to others by taking
appropriate action (stay home; cough etiquette; hand hygiene;
cover wounds; safe disposal of waste; cleaning; laundry; etc.).
Hygienic behavior, however, remains at the mercy of personal
choice even if it favors the individual as well as others (Curtis
et al., 2011). It would be difficult to enforce appropriate behavior
without privacy impositions or, indeed, 24-h surveillance, both
of which are markedly more unethical than the behavior they are
meant to deter. Pathogens are microscopic, which means that the
immediate outcome of unhygienic practices can only be surmised
rather than proven.
Raw meat, vegetables, and other foods may be contaminated
by pathogens at the point of sale (Fox et al., 2017). If there is
insufficient washing or cooking of produce, then organisms are
ingested that both infect, and/or colonize, for later complications.
Even non-infective microbes pose a risk from contaminated
foods, because they may harbor AMRs, which the consumer
could retain for years to come. This compromises future
management of infection for that individual. The gastrointestinal
tract offers an ideal environment for microbial gene exchange
(Smillie et al., 2011). Herein, is specific moral responsibility
for food suppliers and distributors to manage contamination of
foodstuffs at every point in the food chain. The same applies for
dirty water, although water quality usually depends upon existing
public health and sanitation structures (Lyimo et al., 2016).
Pathogen transmission is especially prevalent in hospitals,
due to the close proximity of compromised patients. Hospital-
acquired infections (HAIs) can seriously harm patients, prolong
hospital stay and initiate costly outbreaks. Many hospitals
implement preventive measures to control HAIs, such as
hand hygiene, patient screening, isolation, barrier methods,
ventilation, and cleaning practices. Isolating patients, while useful
for containing the spread of infection, brings its own ethical
considerations (Abad et al., 2010). Screening patients has also
been subjected to ethical debate, especially when it constitutes
an invasive assault on a patient (e.g., genital swabbing) (Millar,
2009). Why inflict such a procedure on a patient if it is not
going to benefit that patient? The patient at risk of MDRO
carriage may not necessarily care if he or she shares his or her
untreatable parasite with other people. While doctors are obliged
to practice beneficence, patient behavior remains exempt from
similar restriction.
Most infection prevention activities lack hard evidence except
for hand hygiene and cleaning. Cleaners do not always clean
thoroughly, however, and clinical staff do not always wash
their hands. This has encouraged a range of monitoring
strategies along with threats (‘zero tolerance’) to improve and
maintain hygiene standards (Dancer, 2010). Thus, ‘stewardship’
for infection prevention and control revolves around monitoring
and feedback, which challenges wellbeing and even employment
prospects for staff (Dancer, 2010). Hand hygiene itself, with
repeated reminders, threats and audits, can cause the avid
practitioner much grief with sore or blistered hands. Cleaning
staff are expected to use powerful disinfectant chemicals for
decontaminating the hospital environment; these, also, can cause
personal discomfort, for both respiratory system and skin,
whether or not they have been appropriately managed (Zock
et al., 2010).
Further concerns have been raised over microbiocidal
products used in healthcare following confirmed links between
disinfectants and resistance (Sattar, 2010). There has even been
a call for regulatory use (Kampf, 2016). Powerful disinfectants
harm the surface ecology, much like antibiotics harm healthy
gut flora, permitting naturally tolerant or resistant microflora to
survive and create reservoirs of increasingly resistant microbes
(Dancer, 2013a). People at home or hospital staff may do more
harm than good by routinely using these products; and toxicity
and cost offer further challenges. Ethical arguments exist over
routine exposure of environments to potent disinfectants, given
that links have been demonstrated between these chemicals and
MDROs. The FDA has recently issued a mandate to disinfectant
companies to justify the components of their produce or remove
them from sale (US Food and Drug Administration [FDA],
2016).
Ultimately, responsibilities for infection control fall to
everyone, whether they are healthcare staff or not. However, there
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should be a balance between specific preventive interventions and
the damage they may do to budgets, environment and human
well-being. In the past, people with untreatable infections such
as syphilis and tuberculosis were subjected to a range of public
health interventions including imprisonment in order to curtail
spread of disease (Kousoulis et al., 2011; Abrams, 2013). Public
health bodies may be faced with similar ethical dilemmas this
century (Littmann et al., 2015).
ALTERNATIVE THERAPIES
There is a range of alternative anti-infectives, both ancient and
modern. These include ‘old fashioned’ remedies such as cranberry
juice; honey; maggots; salt; heavy metals such as silver and
copper, sunlight and fresh air; homeopathy; plants, herbs, and
spices; or more recently, electrolysed water; UV irradiation;
antimicrobial peptides; phage therapy; immunological strategies
and nanotechnology (Dancer, 2013b). There is a risk that
desperate folk seeking therapy for untreatable infection might
experiment with untried, untested, and highly dubious therapies.
These alternative solutions also dictate their own ethical debate
over efficacy, toxicity, and cost. Few have been subjected to
blinded randomized trials and therefore remain controversial.
Indeed, setting up a double blind randomized clinical trial on
exposure to fresh air, for example, would pose considerable
challenge, despite nursing patients with tuberculosis outdoors
just a few decades ago. Since there are ongoing studies on
many of these alternative therapies, it appears that concern
over AMR has tipped equipoise so that studies on these
‘old wives’ remedies are now regarded as legitimate ethical
enquiry.
Doctors can circumvent prohibited use of novel drugs by
following established guidance on unconventional prescribing
(Montanaro et al., 2016). Some remedies already mentioned are
not medicines, but foodstuffs, natural products or irrigants. There
are no formal policies for use, although it is well-recognized
within the medical profession that ‘compassionate’ use of an
unlicensed product is permissible, provided the prescriber and
patient have considered the evidence, discussed all options and
agreed on management. Such prescribing should always be
performed openly, with appropriate documentation. Perhaps
novel products that do show promise from compassionate use
will spur researchers to set up formative clinical trials and thus
potentially benefit everyone (Raus, 2016).
CONCLUSION
Many of the activities described in this article would forestall
the spread of AMR to a greater or lesser extent, provided they
are implemented and upheld by the correct authorities. While
there is no question over the need to institute control initiatives
now and for the future, we should remember that biologic
antimicrobials are ultimately doomed to fail. It is happening
now, and will continue to happen, due to widespread use and
selection pressure from antimicrobial agents. AMR is a simple
illustration of Darwinian evolution, in that any drug, which
impedes a biological process (without killing the organism), will
initiate a microbial mechanism to resist the insult (Rodríguez-
Rojas et al., 2013). Microbes, like man, are programmed to
survive.
While this article has attempted to balance the principles
of bioethics against antimicrobial stewardship, it has uncovered
a complex minefield. Do policy makers have the right to
gamble upon; dictate; or even enforce, current antimicrobial
choice? If effective therapy is urgently required for an individual,
or outbreak situation, then should specific populations be
denied helpful and even potentially lifesaving drugs (Littmann
and Viens, 2015)? A septic patient should receive best guess
empirical therapy; without condemnation of either prescriber
or recipient. Perhaps we should try harder to improve
current prescribing practices, regardless of what may or may
not happen in the future. Indeed, traditional understanding
of bioethical principles contemplates only the here and
now; prescribing amoxicillin to a patient with suspected
urinary tract infection, ticks all the boxes for beneficence
without due recognition of the future consequences for
that patient, others, and environment. Maybe that explains
why current measures remain undefined, insufficient and
subject to prescriber whim. There is evidence from the
consumption rates in hospitals and community to demonstrate
that antibiotics are still being overprescribed, and these data
do not include over-the-counter or internet sources (Millar,
2012).
If humanity only has the privilege of antibiotics for a short
time, there should be more effort toward conserving drugs before
populations are devastated by untreatable infection (Littmann
et al., 2015). Multi-drug resistant tuberculosis has swept across
countries that lack public health infrastructure, now delivering
a global threat courtesy of travel and migration. India is home
to the world’s largest epidemic of MDRTB, which affects 2
million people every year, with a death roughly every 2 min
(Overdorf, 2015). Some strains are resistant to all previously
active antibiotics, thus rendering them completely untreatable.
It cannot be a coincidence that the ‘White Plague,’ as TB was
termed a century ago, originally stimulated the search for a ‘magic
bullet’ for infection. Now MDRTB requires immediate global
initiative to fund yet more research and development into finding
alternative therapies.
Controlling AMR does not have one single solution but
there are strategies that have immediate effect. Firstly, infection
prevention and control (Aiello et al., 2006; Dancer, 2013b). If
infections are adequately contained, then horizontal transmission
of multi-resistant bacteria will be decreased. While individuals
have a moral responsibility for personal hygiene, multiple
organizations clearly have judicial responsibility toward infection
control. It is not difficult to embed a framework for infection
prevention into healthcare, public buildings, schools, colleges,
industry, food establishments, and even private households
(Bloomfield, 2015). Hand hygiene and cleaning provide simple
yet fundamental practices for breaking the chain of infection
(Curtis et al., 2011). Contractual cleaning specifications are a
lot easier to implement than activities that rely upon behavioral
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decisions, i.e., hand hygiene, even if the latter is underpinned by
ethical education or conscience.
Secondly, much more can be done toward stewardship
practices in hospitals, community and indeed, worldwide. There
are still too many antimicrobial agents used inappropriately
and unnecessarily, and mandatory restrictions are probably
just around the corner. A crack down on internet, black
market, and over-the-counter sales ought to receive immediate
attention. There may also be a call for implementing an
antimicrobial prescribing license for all prescribers, underpinned
by prioritizing basic education on microbiology and anti-
infectives.
Thirdly, more incentives are required for companies and
academic institutions to initiate research into new drugs and
vaccines, including novel methods for managing infection.
Granting or investing in financial support for small drug
companies and businesses to aid research allows early exploration
of compounds and vaccines discovered by scientists and doctors.
One of these could result in the single most important
medical and scientific breakthrough of the 21st century.
Approval agencies need to accelerate new medicines, balanced
against regulatory hurdles, while conserving safety and efficacy
standards.
Fourthly, there is need for greater international collaboration
and accountability distribution, with broader engagement
of countries and United Nations agencies to foster global
intersectoral action on AMR (Jasovský et al., 2016). This includes
agreed definitions for surveillance and support for analyses and
reporting of trends on a worldwide basis. Control of disease and
its causes is impossible without surveillance and international
liaison. More understanding of the economic analyses which help
drive health behaviors on antimicrobial use would benefit policy
makers and stewardship strategies (Eggleston et al., 2010).
Finally, it is time for a widespread public awareness campaign
in order to educate everyone about the potential loss of anti-
infective drugs (Micallef et al., 2017). Social media and television
reach far more people than notices pinned up in doctors’
clinics. Although there is no better public awareness than a fatal
outbreak of multi-resistant bacteria (or a celebrity succumbing to
untreatable infection), governments and societies should educate
the public about AMR now and how it affects them and future
generations. Making it personal will challenge ignorance. For
prescribers themselves, discussion on the traditional definitions
of bioethical principles might contribute toward a deeper
understanding of AMR and provide the support required to
modify prescribing behavior on a global basis.
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